Data / Research funding / Florida / Aqualung Therapeutics Corp.
Aqualung Therapeutics Corp.: 7 NIH awards ($9.8M), fiscal years 2021 to 2026
Aqualung Therapeutics Corp. in Juno Beach, FL is funded under 7 NIH awards ($9.8M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- MKDKZ3ZZ99A2
- State
- Florida
Awards
7 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,457,594 | June 1, 2019 | August 31, 2025 | GARCIA, JOE G. N. | reporter.nih.gov |
| Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,219,663 | September 19, 2022 | July 31, 2025 | GARCIA, JOE G. N. | reporter.nih.gov |
| eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,000,000 | June 1, 2020 | May 31, 2023 | GARCIA, JOE G. N. | reporter.nih.gov |
| Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,877,612 | September 1, 2022 | August 31, 2025 | GARCIA, JOE G. N. | reporter.nih.gov |
| Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | NIH | National Heart, Lung, and Blood Institute | 2021 | $750,000 | June 1, 2019 | April 30, 2022 | GARCIA, JOE G. N. | reporter.nih.gov |
| Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression | NIH | National Heart, Lung, and Blood Institute | 2025 | $284,699 | September 20, 2025 | September 19, 2026 | MIELE, STANLEY | reporter.nih.gov |
| Targeting the P Selectin Pathway to Improve ARDS Survival | NIH | National Heart, Lung, and Blood Institute | 2022 | $259,613 | September 23, 2022 | September 22, 2023 | MIELE, STANLEY | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1 | $284,699 | 0 | $0 |
| 2024 | 3 | $2,741,808 | 0 | $0 |
| 2023 | 3 | $3,284,215 | 0 | $0 |
| 2022 | 4 | $1,788,459 | 0 | $0 |
| 2021 | 2 | $1,750,000 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Biotechnology
- Lung
- Orphan Drug
- Rare Diseases
- Acute Respiratory Distress Syndrome
- Immunization
- Immunotherapy
- Infectious Diseases
- Pulmonary Fibrosis
- Biodefense
- Cancer
- Emerging Infectious Diseases
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.